Winston Tan

6.0k total citations · 2 hit papers
117 papers, 3.6k citations indexed

About

Winston Tan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Winston Tan has authored 117 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 35 papers in Cancer Research. Recurrent topics in Winston Tan's work include Prostate Cancer Treatment and Research (44 papers), Cancer Genomics and Diagnostics (17 papers) and HER2/EGFR in Cancer Research (13 papers). Winston Tan is often cited by papers focused on Prostate Cancer Treatment and Research (44 papers), Cancer Genomics and Diagnostics (17 papers) and HER2/EGFR in Cancer Research (13 papers). Winston Tan collaborates with scholars based in United States, Canada and Australia. Winston Tan's co-authors include David W. Hillman, Gerardo Colón‐Otero, Marlon C. Rebelatto, Peter H. O’Donnell, Zev A. Wainberg, John A. Blake-Haskins, Jason J. Luke, John F. Kurland, Ashok Gupta and Michael S. Gordon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Winston Tan

108 papers receiving 3.5k citations

Hit Papers

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Pro... 2016 2026 2019 2022 2016 2020 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
    2016 661 citations Winston Tan et al. profile →
  2. Management of Cancer Cachexia: ASCO Guideline
    2020 373 citations Winston Tan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Winston Tan United States 27 1.4k 1.1k 873 690 645 117 3.6k
Panagiotis Paliogiannis Italy 32 1.3k 0.9× 1.1k 1.0× 990 1.1× 461 0.7× 528 0.8× 179 3.9k
Haojie Li China 27 912 0.6× 1.1k 1.1× 1.0k 1.2× 675 1.0× 684 1.1× 137 3.8k
Shiying Yu China 31 1.3k 0.9× 926 0.9× 1.5k 1.7× 870 1.3× 459 0.7× 141 3.7k
Deborah Mukherji Lebanon 30 1.4k 1.0× 896 0.8× 1.2k 1.3× 652 0.9× 476 0.7× 183 3.4k
Jaime Feliú Spain 35 2.5k 1.8× 1.1k 1.0× 1.2k 1.4× 790 1.1× 667 1.0× 245 4.4k
Masashi Ando Japan 31 2.0k 1.4× 954 0.9× 688 0.8× 774 1.1× 431 0.7× 206 3.6k
Brett Hughes Australia 31 2.3k 1.6× 2.1k 2.0× 820 0.9× 696 1.0× 375 0.6× 179 4.4k
Tom R. Fitch United States 34 2.0k 1.4× 1.3k 1.2× 1.2k 1.3× 813 1.2× 763 1.2× 97 4.6k
D. Amadori Italy 35 1.8k 1.3× 1.1k 1.0× 739 0.8× 915 1.3× 701 1.1× 173 3.9k
Julio M. Pow‐Sang United States 38 1.3k 0.9× 1.3k 1.2× 1.1k 1.2× 506 0.7× 1.7k 2.7× 214 4.7k

Countries citing papers authored by Winston Tan

Since Specialization
Citations

This map shows the geographic impact of Winston Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Winston Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Winston Tan more than expected).

Fields of papers citing papers by Winston Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Winston Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Winston Tan. The network helps show where Winston Tan may publish in the future.

Co-authorship network of co-authors of Winston Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Winston Tan. A scholar is included among the top collaborators of Winston Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Winston Tan. Winston Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tan, Winston, Hui Chen, Joel Henderson, et al.. (2025). Digital pathology assessment of kidney glomerular filtration barrier ultrastructure in an animal model of podocytopathy. Biology Methods and Protocols. 10(1). bpaf024–bpaf024. 1 indexed citations
2.
Sicotte, Hugues, Krishna R. Kalari, Sisi Qin, et al.. (2022). Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment. Molecular Cancer Research. 20(12). 1739–1750. 9 indexed citations
3.
Tofthagen, Cindy, Adam Perlman, Pooja Advani, et al.. (2022). Medical Marijuana Use for Cancer-Related Symptoms among Floridians: A Descriptive Study. Journal of Palliative Medicine. 25(10). 1563–1570. 7 indexed citations
4.
Tan, Winston, et al.. (2022). The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer. Cancers. 14(6). 1361–1361. 7 indexed citations
5.
Fong, Lawrence, Michael J. Morris, Oliver Sartor, et al.. (2021). A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 27(17). 4746–4756. 33 indexed citations
6.
Thong, Melissa S. Y., Raymond J. Chan, Corina van den Hurk, et al.. (2020). Going beyond (electronic) patient-reported outcomes: harnessing the benefits of smart technology and ecological momentary assessment in cancer survivorship research. Supportive Care in Cancer. 29(1). 7–10. 20 indexed citations
7.
Kohli, Manish, Winston Tan, Tiantian Zheng, et al.. (2020). Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine. 54. 102728–102728. 89 indexed citations
8.
Kumar, Vivek, Sikander Ailawadhi, Aditya Mehta, et al.. (2019). Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal. 9(10). 75–75. 44 indexed citations
9.
Chumsri, Saranya, Jeff Sperinde, Heshan Liu, et al.. (2018). High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clinical Cancer Research. 24(13). 3053–3058. 23 indexed citations
10.
Giridhar, Karthik V., Cristobal T. Sanhueza, David W. Hillman, et al.. (2018). Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 21(3). 431–437. 19 indexed citations
11.
Hart, Steven N., Marissa S. Ellingson, Peter T. Vedell, et al.. (2016). Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 6(4). e010332–e010332. 28 indexed citations
12.
Knutson, Keith L., Raphael Clynes, Barath Shreeder, et al.. (2016). Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Research. 76(13). 3702–3710. 47 indexed citations
13.
Ho, Thai H., Daniel Serie, Mansi Parasramka, et al.. (2016). Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. Annals of Oncology. 28(3). 604–610. 67 indexed citations
14.
Roemeling, Christina A. Von, Laura A. Marlow, Simon Cooper, et al.. (2013). Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 19(9). 2368–2380. 224 indexed citations
15.
Tan, Winston, et al.. (2013). Ataxia in a patient with urothelial carcinoma: Pathologic confirmation, recovery, and improved survival. 11(7). 465–467. 3 indexed citations
16.
17.
18.
Tan, Winston, Michael G. Heckman, Prakash Vishnu, et al.. (2012). Effect of Leuprolide on Serum Amyloid-β Peptide Levels and Memory in Patients With Prostate Cancer With Biochemical Recurrence. Urology. 81(1). 150–154. 7 indexed citations
19.
Hines, Stephanie L., et al.. (2007). The Role of Mammography in Male Patients With Breast Symptoms. Mayo Clinic Proceedings. 82(3). 297–300. 29 indexed citations
20.
Iczkowski, Kenneth A., et al.. (2006). Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Research. 16(9). 750–758. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Panagiotis Paliogiannis Breakdown of academic impact, for papers by Haojie Li Breakdown of academic impact, for papers by Shiying Yu Breakdown of academic impact, for papers by Deborah Mukherji Breakdown of academic impact, for papers by Jaime Feliú Breakdown of academic impact, for papers by Masashi Ando Breakdown of academic impact, for papers by Brett Hughes Breakdown of academic impact, for papers by Tom R. Fitch Breakdown of academic impact, for papers by D. Amadori Breakdown of academic impact, for papers by Julio M. Pow‐Sang
Rankless by CCL
2026